



IPO Note

SAI PARENTERAL'S LIMITED

Mar 24th, 2026

SAI



Mar 24th, 2026**Details of the Issue**

| | |
|------------------|---------------------|
| Price Band | ₹ 372 - ₹ 392 |
| Issue Size | ₹ 409 Cr |
| Face Value | ₹ 5 |
| Bid Lot | 38 |
| Listing on | BSE,NSE |
| Post Issue Mcap | ₹ 1,731.83 Cr |
| Investment Range | ₹ 14,136 - ₹ 14,896 |

Important Indicative Dates (2025)

| | |
|--------------------|----------|
| Opening | 24 - Mar |
| Closing | 27 - Mar |
| Basis of Allotment | 30 - Mar |
| Refund Initiation | 01 - Apr |
| Credit to Demat | 01 - Apr |
| Listing Date | 02 - Apr |

Lead Manager

Arihant Capital Market Ltd

Offer Details

| | |
|-------------|----------|
| Offer Size | ₹ 409 Cr |
| Fresh Issue | ₹ 285 Cr |
| OFS | ₹ 124 Cr |

| Type | In Rs Cr | No of Shares (Mn) | | % of Issue |
|----------|----------|-------------------|-------|------------|
| | | Upper | Lower | |
| QIB | 205 | 5.22 | 5.50 | 50 |
| NII | 61 | 1.57 | 1.65 | 15 |
| Retail | 143 | 3.65 | 3.85 | 35 |
| Em-ploy. | - | - | - | - |
| Total | 409 | 10.43 | 10.99 | 100 |

Invest Now**Company Profile**

Sai Parenteral's Ltd. is a diversified pharma formulations company engaged in R&D, manufacturing, and marketing, operating across branded generics and CDMO segments for domestic and global markets. Its portfolio spans multiple therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastro, VMS, analgesics, and dermatology, with dosage forms such as injectables, tablets, capsules, liquid orals, and ointments. The company serves government bodies, pharma companies, hospitals, and distributors in India, and has expanded internationally post FY23 through two accredited Hyderabad facilities, catering to regulated and semi-regulated markets across Australia, New Zealand, Southeast Asia, Middle East, and Africa. It operates five manufacturing units (four in Hyderabad and one in Ongole via Revat Laboratories), with certifications including GMP, WHO-GMP, TGA, and PIC/S, and had 298 employees as of Dec 2025.

GEPL's Insights & Investment Thesis:

- Sai Parenteral Ltd is a manufacturer of branded formulations to a diverse customer base in domestic and international markets. The company has transformed itself from a pure injectable player to a diversified formulations business.
- The company had a high cash conversion cycle of 350 days, leading to increased working capital requirement, affecting free cash flow. Due to rise in trade receivable and inventories, the company has been reporting negative operating cash flow.
- Based on the FY25 earnings, relative to the company's paid-up capital, the issue is priced at a P/E ratio of 73x. We believe that the issue is overly valued compared to its peers, experiencing higher cash conversion cycle, negative operating cash flow, and modest financial performance. Therefore, we recommend a "Avoid" rating for the issue.

Business Highlights & Services

The company has successfully transformed from a pure injectable player into a diversified formulations business across multiple dosage forms and therapeutic segments, reducing concentration risk and expanding its addressable market. Its dual model of branded generics and CDMO provides a balanced mix of growth and stability, with CDMO offering long-term, recurring revenues while branded products support margins. The acquisition of internationally accredited facilities has enabled entry into regulated and semi-regulated export markets, acting as a key growth and margin catalyst. With large installed capacity, strategic plant locations near key ports, and increasing customer additions, the company is well-positioned to benefit from operating leverage.

Further, planned capex for capacity expansion, coupled with investments in automation, digital systems, and quality infrastructure, is likely to enhance efficiency and scalability. Strong regulatory certifications and in-house R&D capabilities add to its competitive moat, supporting consistent product development and global compliance. Overall, the company offers a combination of high growth, improving business mix, and margin expansion potential, making it a compelling mid-sized pharma play. The company has strong technical capabilities, integrated execution model, and high-quality, stable revenue streams across both DG set and renewable energy businesses.



Sai Parenteral's CDMO business offers a strong investment lever, driven by its recent entry and rapid scale-up across domestic and international markets, supported by acquisitions of globally accredited facilities that enabled access to regulated markets. The company has built credible long-term relationships with both domestic and global pharma players, with a portion of revenues backed by long-term supply contracts, providing stability and visibility. Its expanding intellectual property base, including in-house developed and approved dossiers along with technology transfers, strengthens its product pipeline, enhances customer stickiness, and supports future market expansion. Further, the acquisition of Noumed adds significant scale to its CDMO platform, especially in the OTC segment, and materially enhances its dossier portfolio, positioning the company for sustained growth, deeper client engagement, and improved revenue visibility in the high-margin CDMO segment.

Sai Parenteral offers a well-diversified business mix across institutional, domestic branded, and export segments, ensuring both scale and revenue visibility. Its strong presence in government tenders provides steady demand but comes with a longer working capital cycle, partly offset by faster cash flows and higher margins from exports. The company is steadily expanding in regulated markets like Australia, supported by accredited facilities and strong execution in scaling acquired assets. Strategic acquisitions, including Noumed, further strengthen its global footprint, CDMO capabilities, and presence in high-value markets. Overall, the company presents a balanced play between stable domestic revenues and high-growth export opportunities, driven by improving business mix and execution strength.

Sai Parenteral's is well position to capitalize the growth on the back of strong industry tailwinds and a clear capacity-led expansion strategy, with injectables one of the fastest-growing pharma segments—driving long-term demand due to better efficacy and rising chronic disease prevalence. The company is scaling its capabilities through planned capex, regulatory upgrades (EU-GMP, PIC/S), and expansion into regulated markets, which are expected to improve realizations and enhance global competitiveness. Its focus on niche, high-value segments such as lyophilized injectables and cartridge-based delivery systems further strengthens margin potential. In parallel, the rapidly growing global CDMO opportunity is being leveraged through an integrated service model, supported by investments in R&D, capacity, and regulatory infrastructure. The acquisition of Noumed adds significant strategic value through long-term supply contracts, a large dossier base, and strong presence in Australia and New Zealand, providing revenue visibility and cross-selling opportunities. Overall, the company is well-positioned to benefit from export growth, CDMO scale-up, and a shift towards high-margin, regulated markets, supporting sustained growth and profitability.

Sai Parenteral's investment appeal is strengthened by its strategic expansion through Noumed, which is developing a TGA-compliant manufacturing facility in Australia to enable in-house production, improving supply chain resilience, margin profile, and alignment with regulated market requirements while ensuring revenue visibility through long-term pharmacy contracts. This backward integration, supported by government funding, enhances competitiveness in high-value markets like Australia and New Zealand, which are witnessing strong CDMO growth. The company is further reinforcing its growth engine through a dedicated R&D centre, accelerating product development, dossier filings, and entry into complex generics, supported by a large and expanding dossier portfolio (including access to 451 Noumed dossiers). With a clear focus on tapping the global generics opportunity, upcoming patent cliff, and expanding presence across regulated and semi-regulated markets, the company is well-positioned to drive export-led growth. Additionally, its proven track record of value-accretive acquisitions, strong institutional relationships, and alignment with India's growing generics demand provide a balanced mix of stability and growth, supporting long-term value creation.

[Product wise revenue breakup](#)

| Particular | 1HFY26 | | FY25 | | FY24 | | FY23 | |
|----------------------|----------------|--------------------|----------------|--------------------|----------------|--------------------|----------------|--------------------|
| | Amount (In Cr) | % of Total revenue | Amount (In Cr) | % of Total revenue | Amount (In Cr) | % of Total revenue | Amount (In Cr) | % of Total revenue |
| Injectables | 22 | 25.29% | 71 | 44.94% | 71 | 47.33% | 89 | 92.71% |
| Tablets | 52 | 59.77% | 57 | 36.08% | 56 | 37.33% | 3 | 3.13% |
| Liquid Orals | 11 | 12.64% | 15 | 9.49% | 15 | 10.00% | 4 | 4.17% |
| Ointments | 0 | 0.00% | 1 | 0.63% | 1 | 0.67% | 0 | 0.00% |
| Capsules | 2 | 2.30% | 4 | 2.53% | 4 | 2.67% | 0 | 0.00% |
| Others | 0 | 0.00% | 10 | 6.33% | 3 | 2.00% | 0 | 0.00% |
| Total Revenue | 87 | 100% | 158 | 100% | 150 | 100% | 96 | 100% |



Business division wise revenue breakup

| Particular | 1HFY26 | | FY25 | | FY24 | | FY23 | |
|-----------------------------|----------------|--------------------|----------------|--------------------|----------------|--------------------|----------------|--------------------|
| | Amount (In Cr) | % of Total revenue | Amount (In Cr) | % of Total revenue | Amount (In Cr) | % of Total revenue | Amount (In Cr) | % of Total revenue |
| Branded Generic Formulation | 63 | 72.41% | 127 | 80.38% | 131 | 87.33% | 91 | 94.79% |
| CDMO | 24 | 27.59% | 31 | 19.62% | 19 | 12.67% | 5 | 5.21% |
| Total Revenue | 87 | 100% | 158 | 100% | 150 | 100% | 96 | 100% |

Parenteral vs Non-Parenteral Business


| Particular | 1HFY26 | | FY25 | | FY24 | | FY23 | |
|----------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|-------------|
| | Amount (In Cr) | % of TR | Amount (In Cr) | % of TR | Amount (In Cr) | % of TR | Amount (In Cr) | % of TR |
| Parenteral | 22 | 25.29% | 71 | 44.65% | 72 | 47.83% | 89 | 91.75% |
| Non-Parenteral | 65 | 74.71% | 88 | 55.35% | 78 | 52.17% | 8 | 8.25% |
| Total Revenue | 87 | 100.00% | 159 | 100.00% | 150 | 100.00% | 97 | 100% |

Domestic vs Export Business

| Particular | 1HFY26 | | FY25 | | FY24 | | FY23 | |
|----------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|-------------|
| | Amount (In Cr) | % of TR | Amount (In Cr) | % of TR | Amount (In Cr) | % of TR | Amount (In Cr) | % of TR |
| Domestic | 66 | 75.86% | 133 | 83.65% | 141 | 94.00% | 94 | 96.91% |
| Export | 21 | 24.14% | 26 | 16.35% | 9 | 6.00% | 3 | 3.09% |
| Total Revenue | 87 | 100.00% | 159 | 100.00% | 150 | 100.00% | 97 | 100% |


Industry Outlook

FIGURE 29. INDIAN PHARMACEUTICAL INDUSTRY SIZE, 2020-2033P, \$ BN



Source: Marketysers analysis

FIGURE 30: INDIA GENERIC PHARMA MARKET, 2021-2033P, \$ BN



Source: Marketysers analysis



Peers Comparison

| Name of the company | Face Value (₹) | Total Revenue (₹ Cr) | EPS | NAV (₹) | P/E (x) | RoNW(%) |
|-----------------------------|----------------|----------------------|-------|---------|---------|---------|
| Sai Parenterals Ltd | 5 | 163 | 5.43 | 35.98 | NA | 15.09 |
| Peers Group | | | | | | |
| Sai Life Sciences Ltd | 1 | 1,695 | 8.61 | 102 | 108 | 7.99 |
| Innova Captab Ltd | 10 | 1,244 | 22.41 | 168 | 32.45 | 13.37 |
| Senores Pharmaceuticals Ltd | 10 | 398 | 16.12 | 176 | 64.30 | 7.18 |
| Gland Pharma Ltd | 1 | 5,617 | 42.40 | 555 | 44.71 | 7.63 |

Company's Competitive Strength

- Diversified generic formulations player with an established track record.
- Strategically located and accredited Manufacturing Facilities.
- Strong focus on CDMO business.
- Well-established distribution network in India and overseas.
- Track record of value-accretive acquisitions.
- Experienced Promoters and Senior Management with extensive domain knowledge.

Key Strategies Implemented by Company

- Branded Generic Formulations.
- Domestic Branded Generic Formulations.
- Branded Generic Formulations (Exports).
- CDMO products & services.
- Research & Development.

| Particular (INR in Cr) | 1HFY26 | FY25 | FY24 | FY23 |
|------------------------|--------|-------|-------|-------|
| Equity Capital | 19 | 13 | 13 | 7 |
| Reserves and Surplus | 190 | 82 | 63 | 24 |
| Net Worth | 209 | 96 | 76 | 31 |
| Revenue | 87 | 163 | 154 | 97 |
| Growth (%) | | 6% | 59% | |
| EBITDA | 16 | 39 | 32 | 18 |
| EBITDAM (%) | 19% | 24% | 21% | 18% |
| PAT | 8 | 14 | 8 | 4 |
| PATM (%) | 8.9% | 8.9% | 5.5% | 4.5% |
| ROE (%) | 5.1% | 15.1% | 11.0% | 13.9% |
| ROCE (%) | 9.3% | 28.9% | 20.5% | 21.0% |



Notes

GEPL Capital Pvt. Ltd

Head Office: D-21/22 Dhanraj Mahal, CSM Marg, Colaba, Mumbai 400001

Reg. Office: 922-C, P.J. Towers, Dalal Street, Fort, Mumbai 400001

Research Analyst – Mr. Vidnyan Sawant | + 022-6618 27687 | vidnyansawant@geplcapital.com

Disclaimer: This report has been prepared by GEPL Capital Private Limited ("GEPL Capital "). GEPL Capital is regulated by the Securities and Exchange Board of India. This report does not constitute a prospectus, offering circular or offering memorandum and is not an offer or invitation to buy or sell any securities, nor shall part, or all, of this presentation form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. This report is for distribution only under such circumstances as may be permitted by applicable law. Nothing in this report constitutes a representation that any investment strategy, recommendation or any other content contained herein is suitable or appropriate to a recipient's individual circumstances or otherwise constitutes a personal recommendation. All investments involve risks and investors should exercise prudence in making their investment decisions. The report should not be regarded by the recipients as a substitute for the exercise of their own judgment. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of GEPL Capital as a result of using different assumptions and criteria. GEPL Capital is under no obligation to update or keep current the information contained herein. The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. Any prices stated in this report are for information purposes only and do not represent valuations for individual securities or other instruments. There is no representation that any transaction can or could have been effected at those prices and any prices do not necessarily reflect GEPL Capital's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions, by GEPL Capital or any other stheirce may yield substantially different results. GEPL Capital makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. Further, GEPL Capital assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Neither GEPL Capital nor any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this report. In no event shall GEPL capital be liable for any direct, special indirect or consequential damages, or any other damages of any kind, including but not limited to loss of use, loss of profits, or loss of data, whether in an action in contract, tort (including but not limited to negligence), or otherwise, arising out of or in any way connected with the use of this report or the materials contained in, or accessed through, this report. GEPL Capital and its affiliates and/or their officers, directors and employees may have similar or an opposite position in any securities mentioned in this document (or in any related investment) and may from time to time add to or dispose of any such securities (or investment). The disclosures contained in the reports produced by GEPL Capital shall be strictly governed by and construed in accordance with Indian law. GEPL Capital specifically prohibits the